Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Gaschler-Markefski

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumorsKlaus Mross, Martin Stefanic, Daniela Gmehling, et al.
British Journal of Cancer|July 1, 2017
Embracing model-based designs for dose-finding trialsSharon B Love, Sarah Brown, Christopher J Weir, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancerSilvia Novello, Rolf Kaiser, Anders Mellemgaard, et al.
The Lancet. Oncology|January 14, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Rolf Kaiser, Anders Mellemgaard, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2016
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trialNasser H Hanna, Rolf Kaiser, Richard N Sullivan, et al.
Oncology Research and Treatment|June 20, 2017
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536Frank Breitenbuecher, Joachim von Pawel, Martin Sebastian, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumorsKlaus Mross, Martin Stefanic, Daniela Gmehling, et al.
British Journal of Cancer|July 1, 2017
Embracing model-based designs for dose-finding trialsSharon B Love, Sarah Brown, Christopher J Weir, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancerSilvia Novello, Rolf Kaiser, Anders Mellemgaard, et al.
The Lancet. Oncology|January 14, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Rolf Kaiser, Anders Mellemgaard, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 2016
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trialNasser H Hanna, Rolf Kaiser, Richard N Sullivan, et al.
Oncology Research and Treatment|June 20, 2017
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536Frank Breitenbuecher, Joachim von Pawel, Martin Sebastian, et al.
Pageof 2